Faculty Collaboration Database

Cardiovascular Risk Assessment and Impact of Medications on Cardiovascular Disease in Inflammatory Bowel Disease. Inflamm Bowel Dis 2021 Jun 15;27(7):1107-1115

Date

09/27/2020

Pubmed ID

32978937

DOI

10.1093/ibd/izaa258

Scopus ID

2-s2.0-85108386474 (requires institutional sign-in at Scopus site)   12 Citations

Abstract

There is increased risk of cardiovascular disease in patients with chronic inflammatory disorders such as rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus. Studies have shown association between cardiovascular disease (eg, myocardial infarction, heart failure, stroke) and inflammatory bowel disease. Medications such as infliximab and adalimumab (monoclonal antibodies to tumor necrosis factor α) may help decrease the inflammatory burden and cardiovascular risk; however, there have been reports of hypertriglyceridemia and worsening of moderate to severe heart failure with these medications. Janus kinase inhibitors, such as tofacitinib, have been associated with hyperlipidemia and thromboembolism. We aim to discuss clinical and imaging modalities to assess cardiovascular risk in inflammatory bowel disease patients and review the role of various medications with respect to cardiovascular disease in this population.

Author List

Sinh P, Cross R

Author

Preetika Sinh MD Associate Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Adalimumab
Antibodies, Monoclonal, Humanized
Cardiovascular Diseases
Humans
Inflammatory Bowel Diseases
Infliximab
Risk Factors